Early detection is crucial in the battle against breast cancer. This systematic review explores the potential of artificial intelligence (AI) in predicting future breast cancer risk using mammograms. We analyze existing studies to evaluate the accuracy, reliability, and clinical implications of AI-driven risk assessment models. By understanding the strengths and limitations of these models, we aim to inform future research and clinical practice.
Breast cancer remains a significant public health concern worldwide. Early detection through regular mammograms has been instrumental in reducing mortality rates. However, mammograms have limitations in predicting future cancer risk. Recent advancements in artificial intelligence (AI) offer promising opportunities to improve breast cancer risk assessment. This review delves into the current state of AI-driven mammography-based breast cancer risk prediction models.
Artificial intelligence has made remarkable strides in various fields, including healthcare. In radiology, AI algorithms have demonstrated exceptional performance in detecting abnormalities in medical images. Specifically, AI-powered mammogram analysis has shown promise in identifying subtle signs of breast cancer that might be missed by human radiologists.
Beyond detecting existing cancers, AI has the potential to predict the likelihood of developing breast cancer in the future. By analyzing mammographic images, AI algorithms can identify subtle patterns and features associated with increased risk. These models could be used to prioritize screening, target preventive interventions, and ultimately reduce breast cancer mortality.
To conduct this review, we systematically searched relevant databases for studies investigating AI-driven mammography-based breast cancer risk prediction. Inclusion and exclusion criteria were defined to ensure the quality and relevance of included studies. The extracted data included study design, sample size, AI algorithm, performance metrics, and clinical implications.
The included studies demonstrated varying levels of accuracy in predicting breast cancer risk using AI-driven mammogram analysis. Several factors influenced model performance, including the type of AI algorithm, dataset size, and image quality. While some studies reported promising results, further research is needed to validate these findings in larger and more diverse populations.
The integration of AI-driven breast cancer risk prediction models into clinical practice could revolutionize preventive care. By identifying women at higher risk, healthcare providers can offer tailored screening and prevention strategies. However, challenges such as model interpretability, ethical considerations, and patient acceptance must be addressed.
AI-driven mammography-based breast cancer risk prediction holds significant promise for improving early detection and prevention. While the field is still in its early stages, the potential benefits are substantial. Continued research and development are essential to refine these models and translate them into clinical practice. By harnessing the power of AI, we can move closer to a future where breast cancer is a preventable disease.
1.
Electronic Sepsis Alerts; Reducing Plaques in Coronary Arteries
2.
Ivonescimab Tops Pembrolizumab in PD-L1-Positive, Advanced NSCLC
3.
Hereditary cancer has a rare and underreported cause.
4.
New imaging guidelines for head and neck cancers, a step toward practice change
5.
BMTs that are "half-matched" are effective in treating severe sickle cell disease.
1.
Oncolytic Adenoviruses Targeting PD-L1: Advancing Cancer Immunotherapy and Tumor Control
2.
Personalized Cancer Vaccines: The Next Frontier in Precision Oncology
3.
Essential Updates in Hematology in Daily Practice
4.
The Predictive Power of Theranostics in Palliative Neuroendocrine Tumor Management
5.
Importance of Early Detection in Oncology
1.
Asian Symposium on Advancement in Hematology and Oncology
2.
Asian Symposium on Advancement in Hematology and Oncology
3.
Asian Symposium on Advancement in Hematology and Oncology
4.
International Cancer Conference
5.
Asian Symposium on Advancement in Hematology and Oncology
1.
A Comprehensive Guide to First Line Management of ALK Positive Lung Cancer - Part VII
2.
Expert Group meeting with the management of EGFR mutation positive NSCLC - Part I
3.
Current Scenario of Cancer- The Incidence of Cancer in Men
4.
Untangling The Best Treatment Approaches For ALK Positive Lung Cancer - Part IV
5.
A New Era in Managing Cancer-Associated Thrombosis
© Copyright 2026 Hidoc Dr. Inc.
Terms & Conditions - LLP | Inc. | Privacy Policy - LLP | Inc. | Account Deactivation